Avelumab
- Generic Name
- Avelumab
- Brand Names
- Bavencio
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1537032-82-8
- Unique Ingredient Identifier
- KXG2PJ551I
- Background
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year, it was also granted approval by EMA and Health Canada, res...
- Indication
Avelumab is indicated for the treatment of adults with metastatic Merkel cell carcinoma (MCC). In the US, it is also used in patients 12 years and older.
...
- Associated Conditions
- Advanced Renal Cell Carcinoma, Metastatic Urothelial Cancer, Locally advanced Urothelial Carcinoma, Metastatic Merkel Cell Carcinoma (MCC)
- Associated Therapies
- First Line Chemotherapy, Maintenance therapy
Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Universitair Ziekenhuis Brussel
- Target Recruit Count
- 36
- Registration Number
- NCT04571632
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Jette, Brussels, Belgium
🇧🇪Uz Brussel, Brussel, Belgium
NPC - AXEL Study : Axitinib-Avelumab
- Conditions
- Interventions
- First Posted Date
- 2020-09-24
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 43
- Registration Number
- NCT04562441
- Locations
- 🇭🇰
Department of Clinical Oncology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- University of Campania "Luigi Vanvitelli"
- Target Recruit Count
- 77
- Registration Number
- NCT04561336
- Locations
- 🇮🇹
Università della Campania Luigi Vanvitelli, Napoli, Italy
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 12
- Registration Number
- NCT04551885
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Hackensack University Medical Center/John Theurer Cancer Center, Hackensack, New Jersey, United States
AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 58
- Registration Number
- NCT04513951
- Locations
- 🇮🇹
U.O. Oncologia Medica 2 Universitaria - Azienda Ospedaliero-Universitaria Pisana Dipartimento di Ricerca Traslazionale e Nuove Tecnologie - University of Pisa, Pisa, Italy
Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2020-12-01
- Target Recruit Count
- 240
- Registration Number
- NCT04504552
- Locations
- 🇮🇹
Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS, Candiolo, Torino, Italy
🇮🇹ASST Spedali Civili di Brescia, Brescia, Italy
🇮🇹Istituto nazionale dei tumori Regina Elena, Roma, Italy
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
- First Posted Date
- 2020-05-13
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 10
- Registration Number
- NCT04387084
- Locations
- 🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Target Recruit Count
- 45
- Registration Number
- NCT04360941
- Locations
- 🇬🇧
Addenbrooke's Hospital Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
🇬🇧The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Ulrik Lassen
- Target Recruit Count
- 300
- Registration Number
- NCT04341181
- Locations
- 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰Rigshospitalet, Copenhagen, Denmark
🇩🇰Odense University Hospital, Odense, Denmark
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT04322643
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.